ABSTRACT
As one would expect, industry’s approach to this field reflects the divergent philosophical views of what is meant by HQL and what its potential role should be in appreciating the benefit or consequence of pharmacologic intervention. The purpose of this chapter is to highlight some of the issues and tensions within the corporate environment that affect industry-sponsored studies and to speculate on how today’s concerns will likely affect the future direction of HQL research.
